Survival predictors in unresectable stage III NSCLC treated with induction chemoimmunotherapy: a real-world multicenter study of treatment cycles, response, and maintenance duration
Translational Oncology · 2027-01 · 75 · 103113
DOI: 10.1016/j.tranon.2026.103113 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Oncology, 2027-01. Verfasst von Yong Shi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Third Xiangya Hospital of Central South University, Central South University, Changsha, 41000, China. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, The Third Xiangya Hospital of Central South University, Central South University, Changsha, 41000, China.
- Department of Oncology, The Third Xiangya Hospital of Central South University, Central South University, Changsha, 41000, China; Xiangya School of Medicine, Central South University, Changsha, 41000, China.
- Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410000, China.
- Department of Radiotherapy, Shaanxi Provincial Cancer Hospital, Xi'an, 710000, China.
- Department of Radiation Oncology, First Ward, Shangqiu First People's Hospital, Shangqiu, 476100, China.
- Department of Radiotherapy, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Center, Kunming, 650032, China.
Zitieren
APA
Shi, Y., Hu, X., Liu, C., Xi, P., Hou, L., Xia, Y., Qi, Y. X., Pan, W., Bai, W., Zhou, H., Hu, H., & Song, Z. (2027). Survival predictors in unresectable stage III NSCLC treated with induction chemoimmunotherapy: a real-world multicenter study of treatment cycles, response, and maintenance duration. Translational Oncology, 75, 103113. https://doi.org/10.1016/j.tranon.2026.103113
Vancouver
Shi Y, Hu X, Liu C, Xi P, Hou L, Xia Y, et al. Survival predictors in unresectable stage III NSCLC treated with induction chemoimmunotherapy: a real-world multicenter study of treatment cycles, response, and maintenance duration. Translational Oncology. 2027;75:103113. doi:10.1016/j.tranon.2026.103113
BibTeX
@article{Shi2027,
author = {Shi, Yong and Hu, Xuanyan and Liu, Chaoyuan and Xi, Pan and Hou, Liangxue and Xia, Yaoxiong and Qi, Yun Xiang and Pan, Wenyan and Bai, Wei and Zhou, Hao and Hu, Hao and Song, Zewen},
title = {Survival predictors in unresectable stage III NSCLC treated with induction chemoimmunotherapy: a real-world multicenter study of treatment cycles, response, and maintenance duration},
journal = {Translational Oncology},
year = {2027},
volume = {75},
pages = {103113},
doi = {10.1016/j.tranon.2026.103113}
}
EUVIMED